EARNINGS & CATALYSTS · October 28, 2026
AbbVie October 30, 2026 earnings preview: growth medicines and research charges
AbbVie reports before open on October 30. Watch Skyrizi and Rinvoq sales, Humira erosion and whether the outlook changes beyond research charges already disclosed.
| Company | Report date | Window | EPS estimate | Revenue estimate |
|---|---|---|---|---|
| AbbVie Inc. (ABBV) | October 30, 2026Issuer confirmed | Before open | 3.73 | 17.32B |
1) When are results due?
AbbVie confirmed results for the quarter ended September 30, 2026 before open on October 30. Its October 5 research-expense update was an outlook adjustment, not the quarterly earnings release.
2) What changed before the report?
On October 5, AbbVie disclosed $216 million of acquired research and milestone expenses, reducing both GAAP and adjusted EPS by 11 cents. It cut full-year adjusted EPS guidance to $13.76–$13.96 from $13.87–$14.07. Separate these research payments from medicine-sales performance.
3) What does the chart show?
At the October 27 close, ABBV was $286.39, above its 20-day average near $277 and 50-day average near $268. Recent trading suggests support around $282–$285 and resistance around $289–$292. Earnings gaps can cross these areas.
4) How the business makes money
AbbVie sells prescription medicines and aesthetics products. Skyrizi and Rinvoq are major growth medicines in immune-related diseases, while Humira faces cheaper competing versions. Watch how sales growth translates into profit and cash flow after research spending.
5) What to watch
Compare Skyrizi and Rinvoq sales with their second-quarter total of $8.03 billion, and check whether Humira declines continue. Watch whether management changes its annual outlook beyond research charges already disclosed. Third-quarter adjusted EPS guidance is $3.73–$3.77.
6) Recently reported peers
Johnson & Johnson reported October 13 revenue of $25.399 billion and adjusted EPS of $2.59, above rounded estimates of $25.38 billion and $2.53. It raised annual adjusted EPS guidance to $11.05–$11.15 from $10.96–$11.11. Shares fell 5.7% at that close versus the prior close. Its different product mix, medical devices and litigation costs limit comparisons with AbbVie.
7) Risks into the report
Medicine pricing and reimbursement pressure can limit growth. Clinical setbacks, competing medicines and research payments can reduce profit. Strong past results or a chart support area cannot prevent a sharp earnings-day move.